Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Weimai is a Chinese digital health company focused on AI-enabled, full-cycle disease management and internet-based healthcare services for public hospitals and patients. The company operates a one-stop healthcare platform spanning pre-hospital, in-hospital, and post-hospital workflows, including appointment booking, follow-up care, maternal and child disease management, remote diagnosis, patient operations, and health management services. Weimai positions itself as a managed-care-style platform tailored to China, using its CareAI technology, data infrastructure, and disease management tools to support hospitals, clinicians, and patient engagement. It is not a traditional therapeutics developer; rather, it is a commercial-stage healthcare services and digital therapeutics platform company with broad deployment across China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Weimai.